이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

당뇨병성 말초 신경병성 통증이 있는 성인 참가자를 대상으로 한 LY3556050 연구

2026년 7월 6일 업데이트: Eli Lilly and Company

당뇨병성 말초 신경병성 통증이 있는 성인 참가자에서 LY3556050을 평가하기 위한 2상, 무작위, 이중 맹검, 위약 대조, 용량 범위 연구

이 연구의 주요 목적은 당뇨병성 말초 신경병증성 통증(DPNP) 참가자를 대상으로 위약 대비 LY3556050의 안전성과 효능을 확인하는 것입니다. 연구는 3개의 연구 기간에 걸쳐 약 24주 동안 지속됩니다.

연구 개요

상태

완전한

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

404

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 대한민국
    • Kyǒnggi-do
      • Sosa-gu, Kyǒnggi-do, 대한민국, 14754
        • Sejong General Hospital
    • Seoul-teukbyeolsi [Seoul]
      • Seoul, Seoul-teukbyeolsi [Seoul], 대한민국, 06351
        • Samsung Medical Center
      • Seoul, Seoul-teukbyeolsi [Seoul], 대한민국, 01830
        • Nowon Eulji Medical Center, Eulji University
      • Seoul, Seoul-teukbyeolsi [Seoul], 대한민국, 05030
        • Konkuk University Medical Center
    • Taejǒn-Kwangyǒkshi
      • Daejeon, Taejǒn-Kwangyǒkshi, 대한민국, 01830
        • Eulji University Hospital
  • 미국
    • Arizona
      • Chandler, Arizona, 미국, 85225
        • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
      • Scottsdale, Arizona, 미국, 85260
        • Headlands Research - Scottsdale
      • Tucson, Arizona, 미국, 85741
        • Orange Grove Family Practice
    • Arkansas
      • Little Rock, Arkansas, 미국, 72211
        • Preferred Research Partners
    • California
      • Canoga Park, California, 미국, 91303
        • Hope Clinical Research, Inc.
      • Northridge, California, 미국, 91325
        • Valley Clinical Trials, Inc.
      • Sacramento, California, 미국, 95821
        • Northern California Research - Sacramento
    • Connecticut
      • Hamden, Connecticut, 미국, 06517
        • CMR of Greater New Haven, LLC
    • Florida
      • Miami, Florida, 미국, 33165
        • New Horizon Research Center
      • Miami, Florida, 미국, 33135
        • Suncoast Research Group
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • Northwestern University
    • Kansas
      • Wichita, Kansas, 미국, 67205
        • Alliance for Multispecialty Research, LLC
    • Kentucky
      • Lexington, Kentucky, 미국, 40509
        • Alliance for Multispecialty Research, LLC
    • Louisiana
      • Lake Charles, Louisiana, 미국, 70601
        • Care Access - Lake Charles
    • Massachusetts
      • Waltham, Massachusetts, 미국, 02451
        • MedVadis Research Corporation
    • Mississippi
      • Ridgeland, Mississippi, 미국, 39157
        • SKY Integrative Medical Center/SKYCRNG
    • Missouri
      • City of Saint Peters, Missouri, 미국, 63303
        • StudyMetrix Research
      • Kansas City, Missouri, 미국, 64114
        • Alliance for Multispecialty Research, LLC
      • Springfield, Missouri, 미국, 65807
        • Clinvest Research LLC
    • Nevada
      • Las Vegas, Nevada, 미국, 89128
        • Las Vegas Medical Research
    • New Jersey
      • East Brunswick, New Jersey, 미국, 08816
        • UniMed Center
    • New York
      • Port Jefferson Station, New York, 미국, 11776
        • North Suffolk Neurology
    • North Carolina
      • Hickory, North Carolina, 미국, 28601
        • Lucas Research - Hickory
      • Morehead City, North Carolina, 미국, 28557
        • Lucas Research, Inc
    • Oregon
      • Medford, Oregon, 미국, 97504
        • Velocity Clinical Research, Medford
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19114
        • Tristar Clinical Investigations
      • West Chester, Pennsylvania, 미국, 19380
        • Suburban Research Associates
    • Tennessee
      • Knoxville, Tennessee, 미국, 37909
        • New Phase Research and Development
    • Texas
      • Austin, Texas, 미국, 78731
        • FutureSearch Trials of Neurology
      • Houston, Texas, 미국, 77040
        • Juno Research
      • Shavano Park, Texas, 미국, 78231
        • Consano Clinical Research, LLC
    • Utah
      • West Jordan, Utah, 미국, 84088
        • Velocity Clinical Research, Salt Lake City
    • Washington
      • Bellevue, Washington, 미국, 98007
        • Northwest Clinical Research Center
      • Renton, Washington, 미국, 98057
        • Rainier Clinical Research Center
  • 일본
      • Fukuoka, 일본, 819-0168
        • Kunisaki Makoto Clinic
      • Osaka, 일본, 559-0012
        • Minamiosaka Hospital
      • Shizuoka, 일본, 422-8006
        • Plumeria DM Clinic
    • Ehime
      • Matsuyama, Ehime, 일본, 790-0067
        • Matsuyama Shimin Hospital
    • Gunma
      • Maebashi, Gunma, 일본, 370-3573
        • Kikuchi Naika Clinic
    • Hiroshima
      • Kure, Hiroshima, 일본, 737-0023
        • Kure Medical Center
    • Hokkaido
      • Asahikawa, Hokkaido, 일본, 070-8530
        • Japanese Red Cross Asahikawa Hospital
    • Kanagawa
      • Yokohama, Kanagawa, 일본, 232-0064
        • Yokohama Minoru Clinic
    • Osaka
      • Suita-shi, Osaka, 일본, 565-0853
        • Medical Corporation Heishinkai OCROM Clinic
    • Saitama
      • Sokashi, Saitama, 일본, 340-0015
        • Sugiura Internal Medicine Clinic
    • Shizuoka
      • Shizuoka, Shizuoka, 일본, 424-0855
        • Suruga Clinic
    • Tokyo
      • Ootaku, Tokyo, 일본, 143-0015
        • Medical Corporation Sato Medical clinic
      • Shinjuku-ku, Tokyo, 일본, 160-0008
        • Heishinkai Medical Group ToCROM Clinic
  • 체코
      • Olomouc, 체코, 779 00
        • Agentura Science Pro
    • Hradec Králové Region
      • Broumov, Hradec Králové Region, 체코, 550 01
        • EDUMED - Broumov
    • Praha 1
      • Prague, Praha 1, 체코, 11000
        • Diabet2 s.r.o., diabetologicka a interni ambulance
    • Praha 6
      • Prague, Praha 6, 체코, 160 00
        • Neurologická Ambulance - Forbeli
    • Praha, Hlavní Mešto
      • Prague, Praha, Hlavní Mešto, 체코, 160 00
        • FLEDIP - Na dlouhem lanu
      • Prague, Praha, Hlavní Mešto, 체코, 140 00
        • DiaVize s.r.o.
    • Rychnov Nad Kněžnou
      • European Union, Rychnov Nad Kněžnou, 체코, 516 01
        • Vestra Clinics
  • 폴란드
    • Greater Poland Voivodeship
      • Poznan, Greater Poland Voivodeship, 폴란드, 61-853
        • Nzoz Neuro-Kard Ilkowski i Partnerzy SPL
    • Kuyavian-Pomeranian Voivodeship
      • Torun, Kuyavian-Pomeranian Voivodeship, 폴란드, 87-100
        • MICS Centrum Medyczne Toruń
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, 폴란드, 31-261
        • Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, 폴란드, 51-162
        • Centrum Badań Klinicznych Piotr Napora lekarze sp.p.
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, 폴란드, 00-874
        • MICS Centrum Medyczne Warszawa
      • Wyszków, Masovian Voivodeship, 폴란드, 07-200
        • Samodzielny Publiczny Zespol Opieki Zdrowotnej w Wyszkow
    • Podlaskie Voivodeship
      • Biaystok, Podlaskie Voivodeship, 폴란드, 15-351
        • Zdrowie Osteo-Medic
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, 폴란드, 40-081
        • Centrum Medyczne Pratia Katowice
      • Katowice, Silesian Voivodeship, 폴란드, 40-648
        • Pro Familia Altera
      • Ruda Śląska, Silesian Voivodeship, 폴란드, 41-709
        • NZOZ Przychodnia Specjalistyczna Andrzej Wittek, Henryk Rudzki
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, 폴란드, 90-338
        • Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

포함 기준:

  • 스크리닝 전 최소 6개월 동안 진단된 제1형 당뇨병(T1D) 또는 제2형 당뇨병(T2D)의 병력 및 현재 진단을 보유해야 합니다.
  • 스크리닝 시점에 헤모글로빈 A1c(HbA1c)가 10 이하인 상태에서 1일 전 최소 90일 동안 안정적인 당뇨병 치료 요법으로 안정적인 혈당 조절을 유지해야 합니다.
  • 참가자 보고서 또는 병력에 근거하여 최소 12주 동안 매일 말초 신경병성 통증의 병력이 있어야 합니다.
  • 선별검사 동안 시각적 아날로그 척도(VAS) 통증 값이 ≥40 및 <95입니다.
  • 하지에 대칭성 당뇨병성 말초 신경병증이 6개월 이상 존재하고 미시간 신경병증 선별검사 기기에서 파트 B ≥3 점수로 진단된 경우
  • 진행 중인 비약물학적 통증 완화 요법(예: 물리 치료)의 일관된 처방을 유지할 의향이 있으며, 연구 참여 중에 새로운 비약물학적 통증 완화 요법을 시작하지 않을 것입니다.

  • 연구 기간 동안 프로토콜에 따라 허용되는 병용 진통제를 제외하고 만성 통증 상태에 대해 복용하는 모든 약물을 기꺼이 중단할 의향이 있는 경우

    • 체질량 지수가 45킬로그램/제곱미터(kg/m²)(포함) 이하입니다.
    • 남성 또는 여성이 생식 및 피임 요건을 준수할 수 있습니까?

제외 기준:

  • DPNP로 인한 통증의 자가 평가를 손상시킬 수 있는 다른 잠재적 원인 및/또는 혼란스러운 통증 원인의 병력.
  • 지난 6개월 이내에 관심 대상 부위에 영구적인 감각 상실을 초래하기 위한 시술(예: 절제 기술)을 받은 경우.
  • 절제로 해소된 피부 기저 세포 또는 편평 세포 암종을 제외하고, 기준 시점으로부터 2년 이내에 암을 앓은 경우.
  • 조사관의 판단에 따라 적극적으로 자살을 시도하고 따라서 자살 위험이 상당히 높은 것으로 간주되는 경우.
  • 연구자의 판단에 따라 급성, 심각 또는 불안정한 의학적 상태 또는 연구 참여를 방해할 수 있는 기타 의학적 질병의 병력 또는 존재가 있는 경우.
  • 선별검사에서 HIV 검사 결과가 양성인 경우.
  • 어떤 이유로든 연구 기간 동안 수술을 계획하십시오.
  • 정신 장애 진단 및 통계 매뉴얼(제5판, DSM-5, 미국 정신의학회)에 정의된 약물 사용 장애가 있는 경우

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: Placebo
Participants received a matching dose of placebo administered orally twice daily (BID) over a period of 12 weeks.
의약품: 위약
구두로 관리.
실험적: Mazisotine 50 mg
Participants received mazisotine 50 milligrams (mg) administered orally BID over a period of 12 weeks.
의약품: Mazisotine
Administered orally.
다른 이름들:
  • LY3556050
실험적: Mazisotine 200 mg
Participants received mazisotine BID orally, starting at 50 mg and titrated weekly, reaching 100 mg BID by Week 2 and a target maintenance dose of 200 mg BID by Week 3, which was then maintained up to Week 12.
의약품: Mazisotine
Administered orally.
다른 이름들:
  • LY3556050
실험적: Mazisotine 400 mg
Participants received mazisotine BID orally, starting at 50 mg and titrated weekly, reaching 100 mg BID by Week 2, 200 mg BID by Week 3, and 300 mg BID by Week 4, until reaching a target maintenance dose of 400 mg BID by Week 5, which was then maintained up to Week 12.
의약품: Mazisotine
Administered orally.
다른 이름들:
  • LY3556050

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Mean Change From Baseline in Average Pain Intensity (API) as Measured by Weekly Average of Numeric Rating Scale (NRS) - Bayesian Model Averaging (BMA) Dose-response Model
기간: Baseline, Week 12
  • The NRS was a single-item numeric scale used to describe pain severity. Participants were asked to rate their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine; a higher score indicates worse outcome (greater pain severity).
  • The mixed-model repeated measures (MMRM) model included the fixed, centered, categorical effects of region, baseline NRS average pain score, as well as concurrent use of allowed concomitant medications (yes vs. no based on interactive web response system [IWRS]), and visit. The adjusted dose response value from the MMRM was used for fitting a Bayesian model averaging (BMA) dose-response model.
  • Posterior mean change from baseline, 95 percent (%) credible interval was derived using Bayesian mixed model repeated measures. Data presented were posterior mean with 95% credible interval.
Baseline, Week 12
Mean Change From Baseline in Average Pain Intensity (API) as Measured by Weekly Average of Numeric Rating Scale (NRS) - Frequentist Repeated Measures (FRM) Analysis
기간: Baseline, Week 12
  • The NRS was a single-item numeric scale used to describe pain severity. Participants were asked to rate their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine; a higher score indicates worse outcome (greater pain severity).
  • The Least Squares (LS) Mean was calculated using a frequentist repeated measures (FRM) analysis, where Change = treatment, time interval, treatment * time interval, region, average baseline pain severity category (mild or moderate versus [vs.] severe), concurrent use of allowed concomitant medication as entered in IWRS (yes versus no).
Baseline, Week 12

2차 결과 측정

결과 측정
측정값 설명
기간
Mean Change From Baseline in Worst Pain Intensity (WPI) as Measured by Weekly Average of Numeric Rating Scale (NRS)
기간: Baseline, Week 12
  • The NRS was a single-item numeric scale used to describe pain severity. Participants were asked to rate their worst pain intensity over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine; a higher score indicates worse outcome (greater pain severity).
  • The LS Mean was calculated using an FRM analysis, where Change = treatment, time interval, treatment * time interval, region, average baseline pain severity category (mild or moderate versus severe), concurrent use of allowed concomitant medication (yes versus no based on IWRS).
Baseline, Week 12
Mean Change From Baseline in Patient-Reported Outcomes Measurement Information System Pain Interference Short Form 8a (PROMIS PI SF8a)
기간: Baseline, Week 12
The Patient-Reported Outcomes Measurement Information System Pain Interference Short Form 8a (PROMIS PI SF8a) was administered to measure self-reported consequences of pain on various aspects of the participant's life within the previous 7 days. The scale consists of 8 items, all measuring a single domain of pain interference, including impact on day-to-day activities, work around the home, household chores, family life, social activities, activities done for fun, enjoyment of social activities, and enjoyment of life. Each item was rated on a 5-point response scale ranging from "not at all" (1) to "very much" (5); the 8 item scores were summed to produce a raw score ranging from 8 (minimum) to 40 (maximum). The raw score was then converted to a T-score with a mean of 50 and a standard deviation of 10; higher T-scores indicate worse outcome (greater pain interference). Range cannot be specified in norm-based scores.
Baseline, Week 12
Mean Change From Baseline in Pain Interference With Sleep
기간: Baseline, Week 12
  • Pain Interference with Sleep was assessed using a single-item measure: "To what extent did diabetic nerve pain interfere with your sleep last night?" Participants responded on a scale from 0 (minimum, "Not at all") to 4 (maximum, "Unable to sleep at all"); higher scores indicate worse outcome (greater sleep interference due to pain).
  • LS Mean was calculated using an FRM analysis, where Change = treatment, time interval, treatment * time interval, region, average baseline pain severity category (mild or moderate vs. severe), concurrent use of concomitant medication (yes vs. no based on IWRS).
Baseline, Week 12
Mean Change From Baseline in Patient-Reported Outcomes Measurement Information System Physical Functioning Short Form 10a (PROMIS PF SF10a)
기간: Baseline, Week 12
The PROMIS PF SF10a was administered to assess self-reported physical function and physical activities across 10 items at the present time.The first 5 items assess current physical limitations (health in doing vigorous activities, walking more than one mile, climbing stairs, lifting or carrying groceries, and bending, kneeling, or stooping), each rated on a 5-point Likert scale ranging from "not at all" to "cannot do". The remaining 5 items are self-reported ability to perform specific physical activities such as chores,dressing themselves, bathing,sitting on and getting up from the toilet, each rated on a 5-point likert scale ranging from "without any difficulty" to "unable to do". The 10 item scores were summed to produce a raw score ranging from 10 (minimum) to 50 (maximum).The raw score was then converted to a T-score with a mean of 50 and a standard deviation of 10; higher T-scores indicate better outcome (greater physical function).Range cannot be specified in norm-based scores.
Baseline, Week 12
Mean Change From Baseline in Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF8b)
기간: Baseline, Week 12
The Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF8b) was administered to assess perceptions of sleep quality, sleep depth, and restoration associated with sleep within the previous 7 days, including perceived difficulties and concerns with getting to sleep or staying asleep, and perceptions of the adequacy of and satisfaction with sleep. The scale consists of 8 items, all measuring a single domain of sleep disturbance. Each item was rated on a 5-point response scale ranging from "not at all" to "very much," "never" to "always," or "very poor" to "very good"; the 8 item scores were summed to produce a raw score ranging from 8 (minimum) to 40 (maximum). The raw score was then converted to a T-score with a mean of 50 and a standard deviation of 10; higher T-scores indicate worse outcome (greater sleep disturbance). Range cannot be specified in norm-based scores.
Baseline, Week 12
Mean Change From Baseline in Patient's Global Impression of Illness Severity as Measured by Patient's Global Impression-Severity (PGI-Severity)
기간: Baseline, Week 12
  • The Patient's Global Impression-Severity (PGI-Severity) is a patient-reported single-item instrument designed to assess the participant's severity of diabetic nerve pain over the past week. The single item is rated on a 5-point Likert scale ranging from 1 (minimum, "very severe") to 5 (maximum, "none"); higher scores indicate better outcome (less pain severity).
  • The LS Mean was calculated using an FRM analysis, where Change = treatment, time interval, treatment * time interval, region, average baseline pain severity category (mild or moderate vs. severe), concurrent use of allowed concomitant medication (yes vs. no based on IWRS).
Baseline, Week 12
Mean Change From Baseline in Patient's Global Impression (PGI) of Illness Status as Measured by PGI-Status
기간: Baseline, Week 12
The Patient's Global Impression-Status (PGI-Status) is a patient-reported single-item instrument designed to assess the participant's status with diabetic nerve pain. Three PGI-Status scales were administered to assess physical activity, usual activity, and sleep disturbance. For physical activity, participants rated their status at the present time; for usual activity and sleep disturbance, participants rated their overall status over the past week. Physical activity and usual activity were each rated on a 5-point Likert scale ranging from 1 (minimum, "extremely limited") to 5 (maximum, "not at all limited"); higher scores indicate better outcome (less limitation). Sleep disturbance was rated on a 5-point Likert scale ranging from 1 (minimum, "very much") to 5 (maximum, "not at all"); higher scores indicate better outcome (less sleep disturbance).
Baseline, Week 12
Patient's Global Impression of Change as Measured by Patient's Global Impression-Change (PGI-Change)
기간: Week 12
The Patient's Global Impression-Change (PGI-Change) is a patient-reported single-item instrument designed to assess the participant's rating of change in diabetic nerve pain since they began taking the study medication. Four PGI-Change scales were administered to assess diabetic nerve pain's impact on physical activities, usual activities, sleep disturbance, and overall change. Each item was rated on a 5-point Likert scale ranging from 1 (minimum, "much worse") to 5 (maximum, "much better"); higher scores indicate better outcome (greater improvement).
Week 12
Mean Change From Baseline in Neuropathy Total Symptom Score-6 (NTSS-6)
기간: Baseline, Week 12
The NTSS-6 assessed the frequency and intensity of 6 diabetic peripheral neuropathic symptoms over the previous 7 days: (1) numbness and/or insensitivity, (2) prickling and/or tingling sensation, (3) burning sensation, (4) aching pain and/or tightness, (5) sharp, shooting, lancinating pain, and (6) allodynia and/or hyperalgesia. Each of the 6 symptoms was rated on two separate response scales: an intensity scale (Does not apply [0], Mild [1], Moderate [2], or Severe [3]) and a frequency scale (Never [0], Occasionally, less than 1/3 of the time [0], Often, 1/3 to 2/3 of the time [0.33], or Almost always, more than 2/3 of the time [0.66]). The total score was calculated as the weighted sum across all 6 symptoms, where intensity was given a weight of 1 and frequency was given a weight of 1/3, yielding a total score ranging from 0 (minimum, no symptoms) to 21.96 (maximum, most severe); higher scores indicate worse outcome (greater neuropathic symptom burden).
Baseline, Week 12
Total Amount of Rescue Medication Use as Measured by Average Daily Dosage
기간: Week 12
Acetaminophen was used as rescue medication during the treatment period. The total amount of rescue medication use was summarized as the average daily dosage at Week 12.
Week 12
Percentage of Participants With at Least One Use of Rescue Medication
기간: Week 12
Acetaminophen was used as rescue medication during the treatment period. The percentage of participants with at least one use of rescue medication at Week 12 was reported.
Week 12
Pharmacokinetics (PK): Plasma Concentration of Mazisotine
기간: Postdose at Week 12
Mazisotine plasma concentration was reported. The Measure Type was Median and the Measure of Dispersion/Precision was Inter-Quartile Range, where the lower and upper limits represented the 5th and 95th percentiles, respectively.
Postdose at Week 12

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Eli Lilly and Company

수사관

  • 연구 책임자: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 10월 5일

기본 완료 (실제)

2025년 6월 11일

연구 완료 (실제)

2025년 6월 11일

연구 등록 날짜

최초 제출

2023년 10월 3일

QC 기준을 충족하는 최초 제출

2023년 10월 3일

처음 게시됨 (실제)

2023년 10월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 30일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 6일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 18509
  • J2P-MC-LXBD (기타 식별자: Eli Lilly and Company)
  • 2023-506127-29-00 (기타 식별자: EU Trial Number)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

익명화된 개별 환자 수준 데이터는 연구 제안 승인 및 데이터 공유 계약 서명 시 안전한 액세스 환경에서 제공됩니다.

IPD 공유 기간

데이터는 미국과 유럽연합(EU)에서 연구된 적응증의 최초 출판 및 승인 후 6개월 후에 이용 가능합니다. 데이터 요청은 무기한으로 제공됩니다.

IPD 공유 액세스 기준

연구 제안서는 독립적인 검토 패널의 승인을 받아야 하며 연구자는 데이터 공유 계약에 서명해야 합니다.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다